Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-07-18
2011-11-01
Ha, Julie (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S001100, C514S017700, C514S021100, C530S317000
Reexamination Certificate
active
08048858
ABSTRACT:
A peptide consisting of 5 to 30 amino acid residues, preferably 9 to 15, most preferably about 12 amino acid residues, comprising a B epitope of a poly-α2,8 sialic acid attached to NCAM which is recognized by an anti-poly-α2,8 sialic acid (PSA) antibody, the use thereof and the preparation of a medicament for modulating NCAM functions, to be administered for the prevention and/or the treatment of neurodegenerative diseases, brain and spine lesions, age-related learning and memory problems, and cancer is disclosed.
REFERENCES:
patent: 6346512 (2002-02-01), Blaschuk et al.
patent: 98/08874 (1998-03-01), None
patent: 00/54805 (2000-09-01), None
patent: 02/46408 (2002-06-01), None
Parkinson's disease from Merck manual, pp. 1-9. Accessed Dec. 7, 2010.
Huntington's disease from Merck manul, pp. 1-2. Accessed Dec. 7, 2010.
Dementia and Alzheimer's disease from Merck manul, pp. 1-17. Accessed Jul. 29, 2009.
Mattson MP, “Pathways towards and away from Alzheimer's disease,” Nature, Aug. 2004, 430: 631-639.
Neurologic disorders from Merck manul, pp. 1-2. Accessed Dec. 7, 2010.
Mulitple Sclerosis information page from NINDS, pp. 1-4. Accessed Mar. 14, 2010.
Steinman L, Zamvil SS, “How to Successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis,” Ann Neurol, 2006, 60: 12-21.
Sriram S and Steiner I, “Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis,” Ann Neurol 2005, 58: 939-945.
J.S. Shin et al.: “Monoclonal Antibodies Specific forNeisseria meningitidisGroup B Polysaccharide and Their Peptide Mimotopes” Infection and Immunity, American Society for Microbiology, vol. 69, No. 5, p. 3335-3342, May 2001. XP-002228383.
Christian M. Hurpin et al.: “Bactericidal Activity of Two IgG2a Murine Monoclonal Antibodies with Distinct Fine Specificities for Group BNeisseria meningitidisCapsular Polysaccharide” Hydridoma, vol. 11, No. 6, p. 677-687, 1992. XP009004404.
Rao Y, Wu X-F, Gariepy J. Rutishauser U, Siu C-H, Identification of a Peptide Sequence Involved in Homophilic Binding in the Neural Cell Adhesion Molecule NCAM, Journal of Cell Biology, 1992, 118(4): 937-949.
Storms SD, Rutishauser U, A Role of Polysialic Acid in Neural Cell Adhesion Molecule Heterophilic Binding to Proteoglycans, Journal of Biological Chemistry, 1998, 273(4): 27124-27129.
Nielsen Claus Schafer
Rougon Genevieve
Schachner Melitta
Torregrossa Pascal
Centre National de la Recherche Scientifique
Ha Julie
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
Schafer-N
Universitaetsklinikum Hamburg-Eppendorf
LandOfFree
Use of poly-α2,8-sialic acid mimetic peptides to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of poly-α2,8-sialic acid mimetic peptides to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of poly-α2,8-sialic acid mimetic peptides to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4287623